Alpha Cognition Inc.

ACOG · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
50
SEC Filings

Business Summary

PART I Business Overview We are a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease (AD), for which there are limited or no treatment options. We focus on the development of commercial manufacturing and commercial sales of ZUNVEYL oral tablet formulation. Our commercial development program for ZUNVEYL is primarily focused on building a long-term care (LTC) commercial team that can focus on providing key...

Next Earnings

Q2 FY2026 — expected 2026-08-22

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionACOGdiscussed_in_filing Cybersecurity
topic_mentionACOGdiscussed_in_filing Trusted Computing
topic_mentionACOGdiscussed_in_filing Blockchain & Crypto
topic_mentionACOGdiscussed_in_filing Supply Chain
topic_mentionACOGdiscussed_in_filing Regulation
topic_mentionACOGdiscussed_in_filing Healthcare & Bio
topic_mentionACOGdiscussed_in_filing Sovereign & Government
topic_mentionACOGdiscussed_in_filing Cybersecurity
topic_mentionACOGdiscussed_in_filing Trusted Computing
topic_mentionACOGdiscussed_in_filing Blockchain & Crypto
topic_mentionACOGdiscussed_in_filing Supply Chain
topic_mentionACOGdiscussed_in_filing Regulation
topic_mentionACOGdiscussed_in_filing Healthcare & Bio
topic_mentionACOGdiscussed_in_filing Sovereign & Government
topic_mentionACOGdiscussed_in_filing Cybersecurity
topic_mentionACOGdiscussed_in_filing Trusted Computing
topic_mentionACOGdiscussed_in_filing Blockchain & Crypto
topic_mentionACOGdiscussed_in_filing Supply Chain
topic_mentionACOGdiscussed_in_filing Regulation
topic_mentionACOGdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001213900-26-037614EDGAR105K words
2025-03-312024-12-310001213900-25-026225EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001213900-25-110061EDGAR23K words
2025-08-142025-06-300001213900-25-076600EDGAR—
2025-05-152025-03-310001213900-25-044163EDGAR—
2024-11-142024-09-300001213900-24-098409EDGAR—
2024-08-122024-06-300001213900-24-067658EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-270001213900-26-035696EDGAR1K words
2026-03-260001213900-26-034778EDGAR—
2026-02-230001213900-26-019355EDGAR—
2026-01-150001213900-26-004765EDGAR—
2025-10-140001213900-25-098739EDGAR—
2025-10-020001213900-25-094911EDGAR—
2025-08-220001213900-25-080012EDGAR—
2025-06-230001213900-25-056752EDGAR—
2025-04-100001213900-25-030683EDGAR—
2025-02-270001213900-25-018138EDGAR—

50 total filings indexed. 33 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001655923
TickerACOG
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedA1

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 5aaf980fa301f8f996968c0c1189943bf3394b6aae4da408eb8652410b10692a
parent: 2de751d1a8a2d009fdcb4d417ea8967e8ed19d9c9edddbca362703b46d16c148
content hash: 1b301e841cd9c0c2c96194596b2d2f68c9e1952f27db2bc5ba14b1cbb1186f53
signed: 2026-04-13T04:43:26.903Z
sources: 7 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf